Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 05:01 ET | Source: Research and Markets

Anti-CD279 (PD-1) Antibody Pipeline Insight Report 2025 Featuring Analysis of 40+ Companies & Drugs Including IBI308 (Innovent Biologics) and Tislelizumab (BeiGene)

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
April 11, 2024 09:15 ET | Source: Research and Markets

Anti-CD279 (PD-1) Antibody Drug Pipeline Research Report 2024: Insights on 40+ Companies Featuring GlaxoSmithKline, Innovent Biologics, BeiGene, and Shanghai Junshi Biosciences

Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Anti-CD279 (PD-1)...
January 29, 2024 05:03 ET | Source: Research and Markets

Nasopharyngeal Cancer Market Set for Exceptional Growth: Forecast Analysis 2024-2034 with Focus on Chemotherapy and Asia-Pacific Region

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Nasopharyngeal Cancer Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.In the recent...
December 19, 2022 08:00 ET | Source: Immix Biopharma, Inc.

ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors

Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid TumorsIMX-110 + Tislelizumab...
February 17, 2021 08:38 ET | Source: Research and Markets

I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential

Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...
June 19, 2020 00:27 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 20, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China

BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 13, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 10, 2020 18:00 ET | Source: BeiGene, LTD.

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
January 21, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...

Next Page keyboard_arrow_right